医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Otsuka Enters Urology Field with Non-Invasive and Continuous Urine Volume Sensor Technology

2015年05月04日 PM03:54
このエントリーをはてなブックマークに追加


 

KANAGAWA, Japan

Lilium Otsuka Co., Ltd., an affiliated company of Otsuka Holdings Co., Ltd., (TOKYO:4578) announced that the National Institute of Advanced Industrial Science and Technology (AIST), UriCare Inc., and Lilium Otsuka signed a contract for research and development and marketing of products using ultrasound urinary volume sensor technology owned by UriCare and AIST.

UriCare has been marketing the unique urinary volume sensor, Yuririn USH-052 (medical device approval number: 21600BZZ00466000) in Japan which is a portable post-void residual measuring and urine volume monitor that allows continuous measurement through the attachment of a flat-type probe to the area of the abdomen corresponding to the bladder, and estimates the volume of urine collected in the bladder with a unique indicator that uses ultrasound. Lilium Otsuka will proceed with development of next-generation versions based on this technology.

“The beauty of this technology is that it can continuously measure urine volume in the bladder. It will contribute efficient control of the appropriate timing of urination, such as through clean intermittent catheterization in patients who have lost the ability to urinate for any reason and through urinary induction by nurse or caregiver during rehabilitation.” commented Isao Shirasaki, President and Representative Director of Lilium Otsuka.

Under the corporate philosophy of “Otsuka-People creating new products for better health worldwide” shared by the Otsuka Group, Lilium Otsuka will contribute to the health of people worldwide by creating new markets.

Lilium Otsuka Co., Ltd. http://www.lilium.otsuka

UriCare Inc. http://www.yuririn.jp/

CONTACT

Lilium Otsuka Co., Ltd.
Keiko Yoshimura, +81-42-704-3822
lilium_info@otsuka.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表